PasireotideSomatostatin analogue medicine
Pasireotide acts at somatostatin receptors and is used in selected hormone-excess disorders. Its benefits and risks depend on the condition and formulation, with glucose control a particularly important consideration.
What is Pasireotide?
Pasireotide is a somatostatin analogue used in defined hormone-excess conditions, including Cushing’s disease and acromegaly. Subcutaneous and depot products have different indications and instructions. 1 2
How it works
It acts across several somatostatin receptor subtypes. In Cushing’s disease, the target includes pituitary ACTH secretion and resulting cortisol excess; acromegaly involves the growth-hormone/IGF-1 pathway. 2
Effects studied
Hormone control in Cushing’s disease
Clinical research evaluates control of excess cortisol. Biochemical control is a distinct outcome from tumour shrinkage or resolution of every symptom.
Evidence: Disease-specific clinical trial. 1
Acromegaly hormone control
Relevant formulations address growth-hormone excess in a separate indication.
Evidence: Product- and formulation-specific information. 2
What does the evidence show?
Condition-specific endocrine trials; archived prescribing information retained
Using the body’s inhibitory signalling
Somatostatin restrains release of several hormones. Pasireotide is an analogue with activity at multiple somatostatin receptor subtypes. That receptor profile helps explain why it has been studied in pituitary disorders involving excessive hormone secretion.
Cushing’s disease and acromegaly are different
In Cushing’s disease, the clinical pathway involves pituitary ACTH and excess cortisol. In acromegaly, growth hormone and IGF-1 are central. A trial measuring cortisol control does not directly answer a question about acromegaly, even though the same medicine can act within both endocrine pathways.
The formulation belongs in the description
Subcutaneous and longer-acting depot preparations have different clinical uses and product instructions. Their instructions cannot be combined into a single regimen. Biochemical control, symptom improvement and changes in tumour size also need separate assessment.
Glucose is a major part of the trade-off
Pasireotide can cause hyperglycaemia that requires active management. Gallbladder, liver and cardiac effects, along with excessive suppression of the target hormone, also need attention. Treatment therefore requires monitoring beyond the hormone being targeted. The phrase “hormone-balancing peptide” leaves both its specific purpose and its potential harms unclear.
Safety & status
Hyperglycaemia is an important treatment issue. Liver, gallbladder and cardiac monitoring, along with avoidance of excessive hormone suppression, may also be relevant. 2
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Why can a hormone-lowering treatment raise glucose?
Pasireotide affects several hormone pathways; its clinical effects are not limited to the hormone being targeted. Hyperglycaemia is a recognised safety issue. 2
Do all formulations treat the same condition?
No. The exact preparation and its indication need to be identified. 2
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Pasireotide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Pasireotide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.